Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
View on PubMed
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
TLDR
Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.
View on PubMed
The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
TLDR
The detection rate of [11C]Choline-PET/CT shows a positive relationship with serum PSA-levels in patients with biochemical recurrence of prostate cancer after primary therapy and allows not only to diagnose but also to localise recurrent disease with implications on disease management (localised vs systemic therapy).
View on Springer
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
TLDR
A molecular imaging TNM system (miTNM, version 1.0) is proposed as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI, designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions.
View on Publisher
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
TLDR
These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer imaging and are needed for implementation of this modality in science and routine clinical practice.
View on Springer
Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
TLDR
The current knowledge of economic evaluations of PET and PET/CT in oncologic applications is reported on and an approach toward the implementation of these tests in future clinical studies is suggested.
View on Publisher
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
TLDR
Using blinded reads and independent lesion validation, this single-arm prospective trial establishes high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer.
View on PubMed
The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
TLDR
The management was changed in more than one third of patients undergoing SSTR PET/CT even when performed after an 111In-Octreotide scan, underlining the clinical impact of SSTRPET/CT.
View on Publisher
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
TLDR
Changes in tumor metabolic activity during chemotherapy predict response, prognosis, and recurrence, and provide the basis for clinical trials in which preoperative treatment is changed for patients without a metabolic response early in the course of therapy.
View on PubMed
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
TLDR
The purpose of this guideline is to assist nuclear medicine specialists to deliver PSMA-RLT as an “unproven intervention in clinical practice”, in accordance with the best currently available knowledge.
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License